ライフサイエンスコーパス: drug screen

1 eening, which was verified by positive urine drug screen).

2 erum alcohol levels and 350 [24.5%] by urine drug screens).

3 the rapid exploration of large combinatorial drug screen.

4 to have antioxidant properties in a previous drug screen.

5 of published data and for analysis of other drug screens.

6 large-scale, and parallel mass spectrometric drug screens.

7 in vivo system suited for rapid genetic and drug screens.

8 pecific small-molecule modulators in primary drug screens.

9 determined by serum alcohol levels and urine drug screens.

10 me, allowing applications such as genetic or drug screens.

11 the stage for implementation in large scale drug screens.

12 cardiac disease and serve as a test bed for drug screening.

13 pplications, including disease modelling and drug screening.

14 n vitro are not suitable for high-throughput drug screening.

15 actical applications in cancer diagnosis and drug screening.

16 heroids mimic the tumor microenvironment for drug screening.

17 rotein, outlining an approach for phenotypic drug screening.

18 timing for cell transplantation studies and drug screening.

19 nology (cancer models) for use in anticancer drug screening.

20 d with treatment outcomes profiles and urine drug screening.

21 oader context of respiratory disease and for drug screening.

22 or in vitro modeling of cardiac fibrosis and drug screening.

23 termed DNA-encoded libraries, accessible for drug screening.

24 evaporative dry-eye disease for high-content drug screening.

25 has been developed towards a high throughput drug screening.

26 for studying specific CPVT mutations and for drug screening.

27 thereby providing an excellent platform for drug screening.

28 ritical when analyzing PTPs, for example, in drug screening.

29 regenerative medicine, disease modeling, and drug screening.

30 ary development and for disease modeling and drug screening.

31 showing great potential for high-throughput drug screening.

32 s, disease diagnostics, and chemotherapeutic drug screening.

33 nmental samples, and can also be applied for drug screening.

34 the migratory capability and anti-metastatic drug screening.

35 ential to enable more physiological in vitro drug screening.

36 n native HD tissue samples and for potential drug screening.

37 the CNS to allow pharmacological testing and drug screening.

38 stem cell research, tissue engineering, and drug screening.

39 study cancer cell migration and anti-cancer drug screening.

40 lene) glycol diacrylate (PEGDA) hydrogel for drug screening.

41 e a good model for further investigation and drug screening.

42 es to perform rapid, large-scale genomic, or drug screening.

43 ology, combinatorial chemical synthesis, and drug screening.

44 o use EHM for iPS-based disease modeling and drug screening.

45 e cannot be used for studies of TANDs or new drug screening.

46 ing of anti-cancer mechanism and anti-cancer drug screening.

47 iothreat detection, clinical diagnostics and drug screening.

48 ne expression profiling, and high-throughput drug screening.

49 ant clones were detected with clone-specific drug screening.

50 igation of the biology of CRC metastasis and drug screening.

51 mechanistic studies of tumor biology and for drug screening.

52 platform for vascular disease modelling and drug screening.

53 development, as well as disease modeling and drug screening.

54 ogical application, disease diagnostics, and drug screening.

55 to have application in cellular imaging and drug screening.

56 period of abstinence and 64% requiring urine drug screening.

57 ved hydrophobic cavity suitable for targeted drug screening.

58 e study of human organogenesis, disease, and drug screening.

59 turing in relation to, e.g., diagnostics and drug screening.

60 for G protein-coupled receptor (GPCR) biased drug screening.

61 tethered spheroid models to high throughput drug screening.

62 rus 2 (SARS-CoV-2) biology and to facilitate drug screening.

63 velopmental pharmacology and toxicology, and drug screening.

64 cancer research, from mechanistic studies to drug screening.

65 ere used to validate the ASYN-CONA assay for drug screening.

66 egy to enable functional genetic studies and drug screening.

67 Twenty-eight studies (n = 65 720) addressed drug screening accuracy.

68 evelop automated, quantitative approaches to drug screening against helminth diseases.

69 Drug screening against helminths has often been phenotyp

70 in the 60 human cancer cell lines of the NCI drug screen and showed potent activity with GI(50) value

71 rafish lateral line system as a platform for drug screen and subsequent validation in the rat cochlea

72 Overall, the combination of a drug screen and transcriptome analysis provides systemat

73 hPSCs) offer many potential applications for drug screening and 'disease in a dish' assay capabilitie

74 logy has progressed as a promising model for drug screening and aiding cancer therapy.

75 Cs) are used as platforms for disease study, drug screening and cell-based therapy.

76 ction of kidney function in both preclinical drug screening and clinical settings.

77 l of the epidemic, and even support targeted drug screening and delivery within the integration of em

78 iagnosis, food safety, environmental health, drug screening and delivery.

79 classifying cells based on their viability, drug screening and detecting populations of malignant ce

80 genetic pathological factors could help with drug screening and development.

81 k in basic biology research, high-throughput drug screening and digital pathology is identifying the

82 personalized cancer medicine at early-stage drug screening and discovery.

83 defects and establish a platform to advance drug screening and disease modeling.

84 used for various applications such as early drug screening and disease modeling.

85 ticipate the widespread adoption of MPSs for drug screening and disease modeling.

86 tial for applications in precision medicine, drug screening and disease risk assessment.

87 PSCs) are essential to personalized in vitro drug screening and disease study.

88 form will greatly facilitate high-throughput drug screening and electrophysiological characterization

89 without the use of solvents, can accelerate drug screening and enable continuous manufacturing, whil

90 LTP in AD, thus opening up a new avenue for drug screening and evaluation of strategies for alleviat

91 ning structure-assisted drug design, virtual drug screening and high-throughput screening.

92 ation of high-quality chemical libraries for drug screening and in applications such as drug repositi

93 This model may provide a platform for drug screening and mechanism studies on solid tumor inte

94 y diverse human sensory neurons suitable for drug screening and mechanistic studies.

95 gs validate a unique BCSC culture system for drug screening and offer preclinical proof of concept fo

96 del can be used for studying high throughput drug screening and other pre-clinical applications.

97 atforms for ultrahigh-throughput combination drug screening and polymerase chain reaction (PCR)-based

98 ul platform in cases such as high-throughput drug screening and prolonged drug release.

99 tiple cell derivatives provide platforms for drug screening and promising treatment options for a wid

100 ion kinetics for many applications including drug screening and the investigation of the mechanisms o

101 ially be used for the treatment of diabetes, drug screening and the study of beta-cell biology.

102 tential applications, including personalized drug screening and therapeutic strategies for liver fail

103 ontractile force screening system useful for drug screening and tissue engineering applications.

104 s massive hiPSC-CM expansion for large-scale drug screening and tissue engineering applications.

105 cs screening-e.g., for clinical phenotyping, drug screening and toxicity testing.

106 We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlo

107 obust protocol for high-throughput anti-RABV drug screens and identified a chemically well-behaved, f

108 udies that will benefit large-scale RNAi and drug screens and in systems beyond C. elegans embryos.

109 Conventional drug screens and treatments often ignore the underlying

110 racterised models for basic cancer research, drug-screening and personalised medicine.

111 t, therefore, be amenable to industrial (eg, drug screening) and clinical (eg, cardiac repair) applic

112 ential of a transcription-based platform for drug screening, and advance two novel lead compounds for

113 nderstanding of cancer pathology, anticancer drug screening, and cancer treatment development.

114 l to produce podocytes for disease modeling, drug screening, and cell therapies.

115 tial cell source for heart disease modeling, drug screening, and cell-based therapeutic applications.

116 f applications such as inflammation studies, drug screening, and coculture interactions.

117 Tissue engineering, gene therapy, drug screening, and emerging regenerative medicine thera

118 llenge for applications in disease modeling, drug screening, and heart repair.

119 e for their application in disease modeling, drug screening, and regenerative medicine.

120 ould have broad utility in disease modeling, drug screening, and regenerative medicine.

121 re unlikely to be found through conventional drug screening, and they include kinase inhibitors and d

122 be used for investigating tumor biomarkers, drug screening, and understanding tumor progression and

123 ystems is crucial for interpreting data from drug screens, and can help control for biases introduced

124 l-based and protein function-based multiplex drug screens, and concurrently discovers therapeutic com

125 Particularly for drug screening applications, high-temporal resolution ce

126 underscoring the potential of the system for drug screening applications.

127 ug formulations and might also be useful for drug screening applications.

128 s very attractive for tissue engineering and drug screening applications.

129 We thus performed a drug screening approach using a library consisting of ep

130 The basis of the next generation of drug-screening approaches is set to be in silico risk pr

131 d by topoisomerase inhibitors in an oncology drug screening array and altered variant composition of

132 viously identified in a large-scale unbiased drug screen as promoting increased lifespan in worms.

133 could serve as a valuable system to expedite drug screening as well as to study intestinal transporte

134 on detector and a system for hypothesis-free drug screens as well as identification of natural suppre

135 which can potentially be used for in silico drug screening, as well as contributing to understanding

136 ritable neurological disorders, and advances drug screening, as well as personalized medicine.

137 cal proteomics and an organotypic cell-based drug screening assay, we determine the functional role o

138 Using a cell-based drug-screening assay, we identified Acriflavine (ACF), a

139 Through a series of further drug screening assays and two-drug combination testing,

140 Fluorescent drug screening assays are essential for tyrosine kinase

141 We show that OC organoids can be used for drug-screening assays and capture different tumor subtyp

142 enerative diseases and in proof-of-principle drug-screening assays.

143 A primary in vitro drug screen assessed cellular proliferation patterns in

144 l microarray imaging approach for anticancer drug screening at specific cancer protein-protein interf

145 lytes, immunoassays, gene expression assays, drug screening, bioimaging of live organisms, cancer stu

146 conduct patient-specific in vivo and ex vivo drug screens, but stromal contributions to treatment res

147 s demonstrate the potential utility of rapid drug screening combined with genomic profiling for preci

148 sing a panel of AMD biomarkers and candidate drug screening, combined with transcriptome analysis, we

149 Doxorubicin was selected from a drug screen consisting of conventional chemotherapeutics

150 Therefore, an OMI organoid drug screen could enable accurate testing of drug respon

151 Next generation drug screening could benefit greatly from in vivo studie

152 FGFR inhibitors was determined by analyzing drug screen data and conducting in vitro and in vivo exp

153 al genes is tested in silico using shRNA and drug screening data from cancer cell line databases.

154 an algorithm that integrates high-throughput drug screening data, comprehensive kinase inhibition dat

155 blicly available, high-quality DNA, RNA, and drug screening data.

156 on data linked to high-quality DNA, RNA, and drug-screening data have not been available across a lar

157 ration of transcriptome-profiling, published drug-screening data, and functional in vitro and in vivo

158 cally available genomic, transcriptomic, and drug-screening data.

159 We apply PhEMD to a newly generated drug-screen dataset and demonstrate that PhEMD uncovers

160 ng framework is tested on benchmark in vitro drug screening datasets.

161 For example, drug screening demonstrated that actinomycin D, which is

162 nal applications of those approaches include drug screening, development of novel molecular therapies

163 of organ-on-a-chip systems, high-throughput drug screening devices, and in regenerative medicine.

164 ssues offer enormous potential as models for drug screening, disease modeling, and regenerative medic

165 recapitulate human responses are needed for drug screening, disease modeling, and, ultimately, kidne

166 In a high-throughput promoter-dependent drug screen, doxorubicin (dox) exhibited this ability, a

167 Using a two-pronged drug screen employing the zebrafish lateral line as an i

168 A positive urine drug screen for tetrahydocannabinol (THC+ status), the p

169 many potential applications in modeling and drug screening for airway diseases.

170 We describe a new approach to proteome-wide drug screening for detection of on- and off-target bindi

171 tool for basic discovery and high-throughput drug screening for G-protein-coupled receptors and ion c

172 feasibility of fast and accurate anti-viral drug screening for inhibitors of SARS-CoV-2 and provides

173 d to be useful for regenerative medicine and drug screening for liver diseases.

174 e used as an indicator of cellular noise and drug screening for noise control.

175 en developed and validated in the context of drug screening for schistosomiasis, one of the most impo

176 sing cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental disorders.

177 in future studies of disease mechanisms and drug screens for effective therapies in arrhythmogenic c

178 enes which can be used for disease modeling, drug screening, gene correction and future in vivo appli

179 hnologies are urgently required for reliable drug screening given a worldwide epidemic of prescriptio

180 Our drug screening has identified the source of the SPR peri

181 of this biosensor in future high throughput drug screening has the important potential to help ident

182 ity of BAs in a platform for high-throughput drug screening (HTS).

183 A high-throughput combination drug screen identified agents that enhanced cell killing

184 High-throughput drug screening identified small molecule inhibitors that

185 These findings show that high-throughput drug screening identifies therapies for medulloblastoma

186 A mandatory drug screen implemented by many countries led to a disco

187 ate this microfluidic device will facilitate drug screening in a relevant microenvironment thanks to

188 tform for genotype-phenotype correlation and drug screening in any human myelin disorder.

189 pigenetic biomarkers through high-throughput drug screening in approximately 1,000 molecularly annota

190 heterotypic cell-cell interactions and novel drug screening in diseased human brain.

191 is reporter-based assay allows for antiviral drug screening in human cell culture at biosafety level

192 ptimized reporter assay allows for antiviral drug screening in human cell culture at biosafety level

193 Our work lays the groundwork for label-free drug screening in pharmaceutical science and industry.

194 logical mechanisms of disease and performing drug screening in the presence of applied mechanical loa

195 to antihypertensive treatment at 6 months by drug screening in urine/plasma samples from 85 patients.

196 systematically by combinatorial CRISPR, drug-drug screening in vitro, and patient-derived xenografts.

197 We first performed large-scale drug screens in C. elegans which uncovered 74 hits.

198 t small molecule drug, among the 97 oncology drugs screened, in promoting heterochromatin formation.

199 omimetic assays for interaction analysis and drug screening involving membrane components.

200 The utility of the metastatic models for drug screening is demonstrated by evaluating the antican

201 The applicability for drug screening is demonstrated by studying the effects o

202 Drug screening is facilitated by the incorporation of a

203 opment of a biomimetic 3D culture system for drug screening is necessary to fully understand the in v

204 Large-scale drug screening is needed to identify compounds with anti

205 need for a liver-on-a-chip tissue model for drug screening is particularly important in tissue engin

206 by a complete cell-based assay for efficient drug screening is performed showing a clear correlation

207 ors may be obscured by a ceiling effect when drug screening is performed under strongly phosphorylati

208 High-throughput drug screening is the standard approach to study the dru

209 such as photodynamic therapy for accelerated drug screening, magnetically guided controlled drug deli

210 ons, we developed an efficient combinatorial drug screening method called the Feedback System Control

211 Advances in high-throughput drug screening methods for small molecules, developments

212 Here, by using in silico drug-screening methods, we discovered that Celastrol, a

213 sely, we integrated a 3D-bioprinted perfused drug screening microfluidics platform.

214 our uncertainty estimates with an additional drug screen of 26 drugs, 10 cell lines with 8 to 9 repli

215 ghlight the PM as a high-fidelity target for drug screening of Kv channels.

216 However, high-throughput drug screening of P450s is limited by poor protein stabi

217 sease subset, we performed medium-throughput drug screening on CEBPA/CSF3R mutant leukemia cells and

218 ng individual, combinatorial, and sequential drug screens on human-derived pancreatic tumor organoids

219 death and axonal degeneration, we performed drug screens on primary rodent neurons and identified th

220 prescription drug monitoring programs, urine drug screens, opioid use disorder risk screening instrum

221 dicting and providing meaningful preclinical drug screening outcomes.

222 o evaluate associations between weekly urine drug screens over a 90-day follow-up period and fNIRS, c

223 associated with fewer opiate-positive urine drug screens (P = .003), lower human immunodeficiency vi

224 , as a result, lead to new clinical care and drug screening paradigms, are discussed.

225 A new study developed a drug screening platform utilizing human beige adipose ti

226 underlying disease mechanisms and for use as drug screening platform, particularly for reagents desig

227 metry imaging with PBCs (MALDI-MSI-PBC) as a drug screening platform.

228 ting the potential utility of our model as a drug screening platform.

229 omatography- mass spectrometry (LC-MS) based drug-screening platform we show that Metformin, a widely

230 Innovative drug screening platforms should improve the discovery of

231 l generic analytical applications, including drug screening, prion strain discrimination, biohazard s

232 as a rapid and reliable in vitro method for drug screening prior to in vivo testing.

233 A hybrid drug screening procedure was proposed and applied to ide

234 itro systems have significantly advanced the drug screening process as 3D tissue models can closely m

235 re modeling and significantly accelerate the drug screening process of macromolecule-ligand complexes

236 tforms demonstrated a higher efficacy in the drug-screening process: due to the liquid folding a high

237 tify all possible states and utilize them in drug screening programs.

238 SM or CSPalpha aggregation as biomarkers for drug screening purposes.

239 nd versatile method which can be applied for drug-screening purposes, allowing the determination of e

240 mation from the descriptions of over 100,000 drug screening-related assays in rats and mice.

241 Furthermore, a combinatorial high-throughput drug screen revealed significantly enhanced cytotoxicity

242 Moreover, a drug screen revealed that JAK3/Suz12 mutant leukemia cel

243 High-throughput drug screening revealed that bromodomain and extra-termi

244 ntegrated RNA sequencing and high-throughput drug screening revealed that the Aurora A kinase (Aurora

245 Drug screening reveals Hsp70 and MEK inhibitor combinati

246 y engraft in recipient mice, and preliminary drug screening reveals mutation-specific vulnerabilities

247 Targeted drug screening reveals that SCLC with high MYC expressio

248 s, and thus, their implementation during the drug screening stage has the potential to more accuratel

249 nt in vitro models of muscle dystrophies and drug screening strategies, as well as providing a source

250 Using this model, we designed a drug screening strategy based on the pupal lethality phe

251 ine to support feasibility of this novel TDS drug-screening strategy.

252 Drug screen studies informed by targeted proteomics iden

253 Drug screening studies for inflammatory skin diseases ar

254 Drug screening studies typically involve assaying the se

255 uired make zebrafish the model of choice for drug screening studies, when a valid disease model is av

256 nsplant platform amenable to high-throughput drug screening studies, yet animals eventually reject tu

257 potential in other clinical applications and drug-screening studies.

258 ntegrative bioinformatic and high throughput drug screening study to define the role of E2F2 in maint

259 This exploratory drug-screening study identified several potential target

260 behavior-based, automated, and quantitative drug screening system using this dnc-1 KD model together

261 )F NMR in establishing a conformation-guided drug screening system, advancing the cell- and structure

262 d on MOCOS expression, and paves the way for drug screening targeting MOCOS and/or the purine metabol

263 re amenable for biomarker identification and drug-screening testing and led to the identification of

264 Applied to promyelination drug screening, the method uniquely enabled the identifi

265 ise for advancing precision medicine through drug screening, though it remains unclear to what extent

266 ity of this organism for large-scale in vivo drug screening, thus providing unprecedented opportuniti

267 ation of specific cardiac subpopulations for drug screening, tissue engineering, and disease modeling

268 cific cardiomyocytes, which are critical for drug screening, tissue engineering, and disease modeling

269 nfection and provide a valuable resource for drug screening to identify candidate COVID-19 therapeuti

270 , and develop platforms for, high-throughput drug screening to identify novel compounds to prevent an

271 This approach may also be adapted for drug screens to identify small molecules that rescue end

272 e system to expand CSCs ex vivo for targeted drug screening, to identify promising novel treatments w

273 Cell culture assays for therapeutic drug screening today are fully automated.

274 N transcription, thus making it an efficient drug screening tool that can be used for therapeutic int

275 llmarks of tissue-based bioassays, including drug screening, tumor dissemination, cell co-culture, an

276 H were defined by history of abuse and urine drug screen (UDS).

277 Finally, a phenotypic drug screen using C. elegans identified podocarpic acid

278 Through a proof-of-principle drug screening using BICA, we found that danusertib, an

279 ies of putative new drugs through systematic drug screening using large chemical libraries provide ho

280 results demonstrate a benefit of performing drug screens using intact animals and provide novel targ

281 he CFTR as a therapeutic target, a cell-free drug screen was established to identify modulators of NB

282 his system's biotechnological application in drug screening was successfully demonstrated by the N-ox

283 n of spheroid microarrays for spheroid-based drug screens was demonstrated by quantifying the dose-de

284 Using data from our large drug screen we predicted, and subsequently demonstrated,

285 d dual-reporter system and a high-throughput drug screen, we identified FDA-approved drugs that can s

286 In a drug screen, we identified leflunomide as an agent that

287 On the basis of a high-throughput drug screen, we provide preclinical proof of concept tha

288 Using an epigenetic pathway-targeted drug screen, we report that inhibitors of DNA methyltran

289 Using RNA sequencing and drug screening, we find that treatment of FLT3 internal

290 Using in vitro drug screening, we identified 211 amino-acid substitutio

291 Through a series of data analysis and drug screening, we identified two compounds (i.e., NSC-3

292 Using known vulnerabilities and available drug screens, we highlighted the importance of integrati

293 Results of thrice-weekly urine drug screens were analyzed using a generalized linear mi

294 al ligand-binding approach for antipsychotic drug screening where competitive binding of a novel APD

295 control livers to design an "educated guess" drug screen, which led to the identification of new, del

296 ve the efficacy and accuracy of OCT in vitro drug screening will greatly contribute to the field of c

297 approaches: a high-throughput combinatorial drug screen with the clinical BET inhibitor PLX51107 and

298 opens a new avenue to early diagnostics and drug screening with high sensitivity.

299 We tested various models for STN drug screening with the aim of identifying the most effe

300 of protein translocation and for inhibitor (drug) screening, with an intensity and rigor unattainabl